The lack of association between albumin use and improved secondary outcomes, such as 30-day AKI, mechanical ventilation duration, ICU length of stay, or short-term mortality, aligns with existing evidence, which has failed to demonstrate a meaningful clinical benefit of albumin [13]. This evidence concerns the gene ALB and acute kidney injury.